| Bioactivity | RTDLDSLRTYTL is an Alpha (v) beta (6) integrin (avb6) inhibitor with high affinity and specificity. RTDLDSLRTYTL binds to avb6 integrin, a peptide sequence that activates cytotoxicity and cytokine production in T cells, such as interferon-gamma. RTDLDSLRTYTL is designed through a chimeric T cell antigen receptor (CAR) so that T cells can be redirected to specifically recognize and attack tumor cells. RTDLDSLRTYTL can be used in the research of cancer immunotherapy and targeted drug development[1]. |
| CAS | 222557-93-9 |
| Sequence | Arg-Thr-Asp-Leu-Asp-Ser-Leu-Arg-Thr-Tyr-Thr-Leu |
| Shortening | RTDLDSLRTYTL |
| Formula | C62H104N18O22 |
| Molar Mass | 1453.60 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Pameijer C R J, et al. Conversion of a tumor-binding peptide identified by phage display to a functional chimeric T cell antigen receptor[J]. Cancer gene therapy, 2007, 14(1): 91-97. |
RTDLDSLRTYTL
CAS: 222557-93-9 F: C62H104N18O22 W: 1453.60
RTDLDSLRTYTL is an Alpha (v) beta (6) integrin (avb6) inhibitor with high affinity and specificity. RTDLDSLRTYTL binds t
Data collection：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.